revelex semaglutide RYBELSUS® Side Effects | RYBELSUS®

Common side effects (affecting 1 in 10 people) include: dizziness burping gas (flatulence) bloating inflammation of the stomach lining (gastritis) reflux or heartburn (gastro-oesophageal reflux disease (GERD)) gallstones hair loss taste changes abnormal skin sensations, like burning, stinging, or pins and needles (dysaesthesia) low blood sugar (hypoglycaemia) in people with type 2 diabetes Uncommon side effects (affecting 1 in 100 people) include: low blood pressure feeling dizzy or lightheaded when standing after sitting or lying down because of a sudden drop in blood pressure fast heartbeat increased pancreatic enzyme levels in blood test results delayed stomach emptying low blood sugar (hypoglycaemia) in people who do not have type 2 diabetes increased levels of bilirubin in your blood, signs include yellowing of the skin and whites of the eyes (jaundice) Contact your doctor, call 999 or go straight to A&E if you experience any of the following rare but serious side effects : allergic reactions this is a medical emergency, call 999 straight away if you get difficulty breathing, swelling of the face and/or throat, dizziness, or fainting changes in vision usually in people with diabetes with known eye problems, speak to your doctor if you notice any changes pancreatitis speak to a doctor straight away if you get nausea, vomiting, or severe, ongoing pain in the stomach and/or back gallstones or gallbladder problems speak to a doctor straight away if you get pain in the upper right side of your stomach, yellowing of the skin or eyes (jaundice), fever, or pale stools kidney problems caused by dehydration make sure youre drinking enough water, and if you have severe vomiting or diarrhoea that lasts more than 24 hours, speak to a doctor severe stomach pain sudden swelling or hip fractures You can find a full list of side effects in the patient information leaflet that comes with your Wegovy pills

Authorities in Europe, Canada, and other regions closely monitor FDA actions

Clinical trials (STEP programme) have demonstrated that Wegovy can lead to significant weight losstypically 1015% of initial body weight over 68 weekswhen combined with lifestyle modifications, though individual responses vary

In our study, we examine: Trends in GLP-1 prevalence, adherence data, and potential obstacles to continued use Impacts on mortality among individuals taking these drugs Implications for assessing metabolic risk and the crucial role electronic health records (EHRs) will play Key results GLP-1s may drive 0.2%0.5% annual mortality improvement, realized over a 20-year period

Sacral nerve stimulation is more effective than optimal medical therapy for severe fecal incontinence: a randomized, controlled study